<DOC>
	<DOCNO>NCT00307502</DOCNO>
	<brief_summary>The purpose study characterise pharmacokinetic profile non-nucleoside analog reverse transcriptase inhibitor ( NNRTIs ) protease inhibitor ( PIs ) , influence individual characteristic pharmacokinetic parameter Spanish population HIV-infected subject .</brief_summary>
	<brief_title>Study Determine Pharmacokinetic Behavior Antiretroviral Drugs Patients Infected HIV</brief_title>
	<detailed_description>The antiretrovirals administer conventionally accord fix dosage system , depend weight individual case certain agent . However , plasma level antiretrovirals follow administration fix dose present mark interindividual variability . Moreover , significant proportion patient treatment PIs present plasma level regard suboptimal previous study . Moreover , correct modification dosage drug , populational data pharmacokinetic behaviour dose interval require . Only integrate information specific characteristic individual possible , use mathematical model , estimate effect modification dosage drug would plasma concentration . However , populational data pharmacokinetic behaviour antiretroviral agent still limited moment , always obtain population similar one apply . Thus , know pharmacokinetic behaviour antiretroviral agent population influence certain individual characteristic behaviour may great interest , since way able tailor dosage antiretrovirals reliably patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>1 . Age high 18 year . 2 . Documented HIV infection ( least one positive Westernblot ) 3 . Stable antiretroviral treatment PI NNRTI , change last 4 week . 4 . Women may fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , negative pregnancy test . 1 . Subjects treatment one PI combination PI NNRTI ( use ritonavir dose 400 mg BID regard second PI ) . 2 . Treatment drug know significant pharmacological interaction investigational drug previous two week . 3 . Unsuitable adherence treatment ( one dose omit last week , two dos omit last two week ) . 4 . Presence clinical finding background gastrointestinal disease digestive surgery may interfere pharmacokinetics medication . 5 . Active consumption alcohol ( &gt; 50 grams/day ) illegal drug ( except cannabis ) . 6 . In case woman , pregnancy breastfeeding . 7 . Record suspicion inability cooperate properly</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>protease inhibitor</keyword>
	<keyword>non-nucleoside analog reverse transcriptase inhibitor</keyword>
	<keyword>pharmacokinetic model</keyword>
	<keyword>treatment experience</keyword>
	<keyword>HIV</keyword>
</DOC>